Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bearish
Shanghai Junshi Biosciences
Watchlist
Shanghai Junshi Bioscience (1877.HK/688180.CH) - Behind the “break Up” with AstraZeneca
Equity Bottom-Up
395 Views
10 Jan 2022 01:05
The insight analyzed Junshi in terms of the potential reasons behind the termination of PD-1 commercialization partnership with AstraZeneca, the outlook, the change of FDA attitude and other concerns.
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Equity Bottom-Up
Japan
Philippines
Event-Driven
Asia ECM
Unpaywalled Insights
South Korea
India
Sell / Short Ideas
Singapore REITs
Trending Insights
More »
[Japan Buybacks] - Japan Bank Metrics, Cross-Holdings and Banks Part 1
NTT DC REIT IPO: Global Index Inclusions Later This Year + A Kicker
SICC A/H Listing - Past Growth Has Been Volatile
HEM: Rolling Resilience
Ohayo Japan | Japan Targeted with 25% Tariff Rate
Top Unpaywalled Insights
More »
China Housing - A Mid-Year Check
Rising OPEC+ Supply & Weak Demand To Drag Crude Price Lower
🧠🎙️ The New Barbarians: AI Agent Edition
Barbarians with Bandwidth: Why Christina Qi Left the Hedge Fund World to Reinvent Data
Curator's Cut: CC Vs DD, Singapore’s IPO Momentum and Pair Trade Ideas Galore
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Chunlizhengda Medical Instruments (1858.HK/688236.CH) - 2023 Full-Year Results May Be Disappointing
19 Sep 2023
Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities
18 Jan 2022
Chunlizhengda Medical Instruments (1858.HK) - Conservative About the Outlook
12 Jan 2022
Shanghai Junshi Bioscience (1877.HK/688180.CH) - Behind the “break Up” with AstraZeneca
10 Jan 2022
The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)
20 Dec 2021
Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?
14 Dec 2021
Shanghai Junshi Bioscience - Here Are the Challenges
24 Mar 2021
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.7
x